The glucagon arm raises energy expenditure by accelerating hepatic fatty-acid oxidation
As a glucagon-like peptide-1 (GLP-1) receptor agonist approved by the FDA for chronic weight management, semaglutide (marketed as Wegovy for obesity) represents a long-term treatment approach rather than a short-term solution
Thats a major finding, especially since it was based on real-world health records from over a million people, said Babak Tousi, M.D., director of clinical trials at Cleveland Clinics Lou Ruvo Center for Brain Health in Cleveland, Ohio
[6] Use on inflamed, infected, or wounded scalp areas may increase irritation risk and is typically deferred until integument integrity is restored
It also increases the proportion of lean body mass
He suggests that the most likely connection is that GLP-1 agonists help to reduce inflammation